138 results about "Liver Cirrhoses" patented technology

The invention relates to the technical field of hepatobiliary patient body data prediction, in particular to a hepatobiliary patient risk early warning method and system based on deep learning. According to the method, the lesion parameters are obtained according to the change of the body data of each dimension in a long time; obtaining a dimension influence degree according to the number of liver cancer patients and the lesion parameter distribution of the liver cirrhosis patients in each dimension; according to the similarity degree of the to-be-analyzed patient and the liver cancer patient in each dimension, the lesion similarity degree is obtained, and prediction parameters of the to-be-analyzed patient are obtained in combination with the dimension influence degree and the lesion parameters. And performing risk prediction on the to-be-analyzed patient according to the prediction parameters. According to the method, the body data of each dimension of the long-term cirrhosis patient is analyzed, and the relevance between the complexity of the judgment process and the body data of each dimension is considered, so that the risk early warning of the long-term cirrhosis patient can be accurately performed.

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of drugs for resisting liver cirrhosis and inhibiting liver inflammations, the drugs comprise lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the drugs are ground and then mixed with food to prepare a drug mixture, and the drug mixture is prepared into the drug for resisting liver cirrhosis and inhibiting liver inflammations. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%, and the mechanism of the lanthanum carbonate for treating the liver cirrhosis is as follows: interference or blocking of activation and proliferation of hepatic stellate cells, inhibition of extracellular matrix generation and promotion of extracellular matrix degradation. According to the invention, a rat liver cirrhosis model is constructed through chemical induction, and the effects of reversing liver cirrhosis and inhibiting liver inflammation are found when a rat is treated by taking lanthanum carbonate orally, so that a new candidate drug is provided for clinical treatment of liver cirrhosis.

The invention relates to the fields of biology, medicine and clinic. The invention specifically relates to application of a reagent targeting an eIF2alpha / ATF4 pathway in treatment of hepatic fibrosis diseases. Based on research of the inventor of the invention, on one hand, the invention discloses application of a reagent for targeted inhibition of an eIF2alpha / ATF4 pathway in preparation of drugs for treating hepatic fibrosis diseases, or application of the reagent in preparation of drugs for preventing liver cirrhosis and / or liver cancer; on the other hand, the invention discloses an application of the eIF2alpha / ATF4 pathway protein and / or the coding gene thereof in screening of drugs for treating hepatic fibrosis diseases, or an application in screening of drugs for preventing liver cirrhosis and / or liver cancer. Another aspect of the invention discloses a pharmaceutical composition comprising an agent for targeted inhibition of expression or activity of an eIF2alpha / ATF4 pathway protein; the invention has considerable application prospects in clinical treatment of hepatic fibrosis diseases.

The invention discloses a traditional Chinese medicine composition for treating liver cirrhosis and a preparation method thereof, and belongs to the technical field of anti-liver cirrhosis traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 10g of polyporus umbellatus, 10g of herba artemisiae scopariae, 10g of radix bupleuri, 10g of charred rheum officinale, 10g of rhizoma coptidis, 10g of charred radix scutellariae, 10g of fructus gardeniae, 15g of herba hyperici japonici, 10g of radix curcumae, 10g of rhizoma alismatis, 10g of radix paeoniae rubra, 10g of radix salviae miltiorrhizae, 10g of cortex magnoliae officinalis, 10g of fructus aurantii, 10g of rhizoma cyperi, 10g of rhizoma sparganii, 10g of rhizoma curcumae, 20g of plantain herb, 10g of turtle shell, 10g of pericarpium arecae, 25g of oven earth and 2g of charred colla corii asini. By providing the traditional Chinese medicine composition formula for treating the liver cirrhosis, the effective rate and the cure rate of the medicine for treating the liver cirrhosis are improved.

The invention discloses a liver cirrhosis microbial marker as well as a screening method and application thereof, and solves the technical problems of few markers, small clinical queue scale and unknown effectiveness in predicting the future liver cirrhosis risk in the existing intestinal flora biomarker research. The method comprises the following steps: by integrating whole genome association research data (GWAS) and 16S rRNA gene sequencing data, screening out candidate microbial differential bacteria related to liver cirrhosis by adopting difference analysis; in combination with LDSC analysis and a double-sample Mendel randomization method, MR related bacteria and LDSC genetic related bacteria are screened from the aspects of causal correlation and genetic correlation; taking an intersection of the differential bacteria, the MR related bacteria and the LDSC genetic related bacteria as a marker; finally, model training is conducted through a machine learning algorithm by means of a data set with sample labels, individual liver cirrhosis risk prediction labels are output, early screening of liver cirrhosis is achieved, and the method can be widely applied to the technical field of intestinal microorganism and data mining.

Featured are methods of identifying (e.g., diagnosing) and / or treating a subject having or at risk of developing a liver disorder, such as liver steatosis, liver fibrosis, liver cirrhosis, and / or liver cancer (e.g., HCC). The methods utilize predictive and / or diagnostic biomarkers for identifying a subject as having or having a risk of a liver disorder. The predictive and / or diagnostic biomarkers described herein can also be used to monitor the status of a subject determined to have liver disorder or a risk thereof during treatment with a liver therapy. Also disclosed are methods of treating a subject determined to have a liver disorder (e.g., liver cancer, such as HCC) or a risk thereof (e.g., by assessing the level of one or more of the disclosed biomarkers by administering a liver therapy to the subject.

The invention discloses an application of a biomarker in evaluating the risk of progressing from autoimmune hepatitis to cirrhosis. The biomarker comprises immune globulin G, and / or an antinuclear antibody, and / or aspartate aminotransferase and alanine aminotransferase. Independent predictive factor indexes of the liver cirrhosis risk of an autoimmune hepatitis patient in the biomarker are as follows: an antinuclear antibody ANA index: log2ANA is greater than or equal to 1.62; the AAR index of the ratio of aspartate aminotransferase to alanine aminotransferase is as follows: AAR is greater than or equal to 1.62; the immune globulin G, namely the IgG index, is greater than or equal to 30.3 g / L. The problems that in the prior art, an AIH risk model does not take cirrhosis as the outcome, visual presentation is lacked, prediction efficiency is insufficient, and clinical early-stage accurate risk layering and diagnosis and treatment decision requirements are difficult to meet are solved.

The present application relates to the technical field of medical information processing, in particular to a liver cirrhosis prognosis risk detection system. After each detection of the patient's liver by the system, the image data can quantify the image liver cirrhosis risk from the morphological changes in the liver region. According to the difference between the actual detection data and the prediction data, and the prognosis response non-normality, the disease progression index is determined. The drug adjustment data is used to determine the drug adjustment degree, and then the liver cirrhosis progression index is obtained. The data lag and the liver cirrhosis progression index are quantified to adjust the detection frequency of the system. The present application enables the system to effectively respond to the patient's condition and generate an effective early warning signal to remind medical staff to perform liver detection when necessary.

The invention relates to a gulcomannan modified mesoporous dopamine targeted multifunctional nano diagnosis and treatment agent and preparation and application thereof.The targeted multifunctional nano diagnosis and treatment agent comprises a carrier and lovastatin, the carrier is a manganese ion coordinated mesoporous polydopamine carrier, and the surface of the carrier is modified with gulcomannan. The diagnosis and treatment agent has a good drug loading rate and a good delivery effect, overcomes the defect of low oral absorption rate of single lovastatin, can carry out MRI imaging monitoring, and provides a new thought for integration of diagnosis and treatment of liver cirrhosis.

Provided herein is a method of diagnosing or prognosing advanced liver fibrosis or liver cirrhosis in a patient. The method is accomplished by determining a score based on the circulating levels in serum of three markers.

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.

The invention belongs to the technical field of biotechnology, and particularly relates to application of an exosome MZF1 protein marker in a liver cirrhosis diagnosis / treatment medicine or reagent, a kit and a detection method. The invention provides an application of an exosome MZF1 protein marker in a liver cirrhosis diagnosis / treatment medicine or reagent, a kit for liver cirrhosis diagnosis / treatment and a detection method of a serum exosome MZF1 protein. The exosome MZF1 protein is used as a marker, a valuable reagent or drug application prospect is provided for early diagnosis and treatment of liver cirrhosis, and help is provided for analysis of more serum exosome proteins applied to liver cirrhosis markers.

The present invention discloses a pharmaceutical composition for treating non-alcoholic steatohepatitis, liver fibrosis and / or liver cirrhosis, which is prepared from the following raw materials in the following weight ratios: 15-50 parts of Astragalus membranaceus, 5-25 parts of turtle shell, 5-25 parts of Angelica sinensis, 10-30 parts of safflower, 10-30 parts of peach kernel, and 1-10 parts of liquorice. The pharmaceutical composition of the present invention for treating non-alcoholic steatohepatitis can reduce serum transaminase, and significantly reduce lipid deposition, liver tissue inflammation and collagen fiber deposition; the composition of the present invention for treating liver fibrosis can significantly reduce liver tissue pathological inflammation and collagen fiber deposition, as well as the numerical values of related indexes such as serum liver function ALT and AST, and at the same time significantly down-regulate the numerical values of related indexes such as serum PⅢP, PCⅣ, HA and LN, significantly inhibit the activation of hepatic stellate cells (HSCs), the central link of liver fibrosis, significantly reduce the activation of NLRP3 inflammasome in liver tissue, reduce HSC autophagy and activation, and has a good therapeutic effect on both liver fibrosis and liver cirrhosis.

The present invention relates to the field of liver disease, and more particularly to a method for determining the presence of chronic plus acute liver failure or for determining the risk of developing ACLF in a patient suffering from cirrhosis or a delayed early stage of ACLF. The invention also relates to a method for distinguishing patients suffering from decompensated liver cirrhosis, acute decompensated liver cirrhosis (ADC) or delayed ACLF from patients suffering from early ACLF or ACLF 1, 2, 3, a method for determining the degree of systemic inflammation and a method for determining the presence of a bacterial infection with sepsis.

The invention provides application of an immune response biomarker in prognosis evaluation of mesenchymal stromal cells in treatment of liver cirrhosis patients, and relates to the technical field of biomedicine, the immune response biomarker comprises MX1 positive monocytes or / and LGALS2 positive monocytes, and the MX1 positive monocytes are MX1 positive monocytes or / and LGALS2 positive monocytes. Screening to obtain a potential biomarker LGALS2 positive mononuclear cell and an MX1 positive mononuclear cell for predicting the MSC treatment dose-effect relationship; compared with a healthy control, the proportion of baseline MX1 positive monocytes of a liver cirrhosis patient is remarkably increased (Plt; 0.01), while the proportion of LGALS2 positive monocytes is significantly reduced (Plt; 0.05) of the substrate (1); the change trend of the biomarker under the same MSC dose and the regulation effect on other immune cell subgroups are identified through sequencing analysis, the dose-effect relationship of MSC-mediated immune regulation can be accurately reflected, and patients with low MSC treatment prognosis recurrence risk can be identified.

The invention relates to a patient decision support system and operating method based on self-care algorithms that evaluate patient activity for patients diagnosed with liver cirrhosis, which is intended to monitor and manage patients' health conditions, provides regular data tracking and personalised recommendations, tracks patients' daily and weekly activities, medication use, diet, and exercise routines, collects and evaluates the data, and presents user-specific recommendations, and which uses artificial intelligence and care algorithms to determine, on the basis of the patient's health data, which treatment and care pathways are the most appropriate.

The invention provides a hybridoma cell strain, a monoclonal antibody, a sensitization latex stock solution, and preparation methods and kits thereof. The method for preparing the sensitization latex stock solution by adopting the monoclonal antibody comprises the following steps: latex microspheres are added into the monoclonal antibody for coupling, the concentration of the monoclonal antibody is 6.2-7.4 mg / mL, and the sensitization latex stock solution is obtained. The kit comprises the monoclonal antibody. The hybridoma cell strain provided by the invention can secrete the CHI3L1 monoclonal antibody, and when the secreted CHI3L1 monoclonal antibody is used for auxiliary diagnosis of hepatic fibrosis and liver cirrhosis, the sensitivity and specificity are very good.

The invention specifically discloses a novel chalcone compound as well as a preparation method, a pharmaceutical composition and application thereof. Experimental results show that the compound shows remarkable anti-inflammatory activity in a lipopolysaccharide stimulated RAW 264.7 cell model, and the anti-inflammatory activity is obviously superior to that of a positive drug dexamethasone; the compound shows a remarkable lipid accumulation inhibition effect in a HepG2 cell model treated by free fatty acid, is obviously superior to a positive drug obeticholic acid, and can be used for developing drugs for treating the non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis and related liver cirrhosis.

The present invention provides ligand-bound copper clusters (CuCs), compositions containing ligand-bound copper clusters, and uses thereof in treating patients with liver cirrhosis.

The invention relates to the technical field of artificial intelligence, in particular to a patient information analysis method based on multi-modal fusion, and the method comprises the steps: obtaining a target liver CT image of a patient, marking the target radiology characteristics of the target liver CT image and the target clinical examination information of the corresponding patient, coding the target liver CT image, and obtaining the image coding characteristics; the method comprises the following steps: marking and coding a target radiology feature to obtain a radiology coding feature, coding clinical examination information to obtain an examination information coding feature, fusing an image coding feature, the radiology coding feature and the examination information coding feature to obtain a cross-modal fusion feature, and using a classification head module in a trained deep learning model to carry out classification on the cross-modal fusion feature. And performing cirrhosis outcome classification on the cross-modal fusion features to obtain a cirrhosis outcome classification result. The fusion features of the liver information of the patient are subjected to outcome classification in an automatic fusion mode, so that the classification result of the liver cirrhosis outcome is predicted more accurately.

The invention relates to a model for predicting the death risk of patients suffering from liver cirrhosis critically ill diseases, and belongs to the technical field of medical examination and severe medicine. Aiming at the problems of complexity and time consumption of existing prognostic scoring of cirrhosis, the invention provides an anion gap AG calculated by using Na < + >, K < + >, Cl <-> and HCO3 <-> of intraday venous blood in an ICU (Intensive Care Unit) as a biomarker, and a high-risk threshold value that AG is greater than 16mmol / L is set. Researches show that the death risks of high-AG patients in 30 days, 60 days and hospitalization are obviously increased, the HR after correction is respectively 1.920, 1.793 and 1.764, and the predicted efficiency AUC is approximately equal to 0.71 and is equivalent to MELD, SOFA, GCS and OASIS. The system comprises an electrolyte detection module, an AG calculation module, a risk grading module and a display module, and can be embedded into an existing ICU information platform to realize rapid, simple, convenient and accurate early death risk early warning.

The application belongs to the field of biological medicine, and particularly relates to a compound for treating liver cirrhosis portal hypertension and application thereof. The compound can be used for preparing a medicine for treating liver cirrhosis portal hypertension. The medicine can achieve the treatment purpose of improving LSEC dysfunction and reducing liver cirrhosis portal pressure without affecting the circulating pressure.

The invention relates to the technical field of medicine, and particularly discloses a liver cirrhosis specific intestinal flora marker composition and application of the liver cirrhosis specific intestinal flora marker composition in noninvasive diagnosis. The intestinal microbial flora is selected from the group consisting of clostridium, Bacteroides, Thalictrum, Wehonor genus, Streptococcus genus, Klebsiella genus, and Prevotella genus; according to the method, a non-invasive solution is provided for screening and diagnosis of liver cirrhosis by detecting a synergistic change mode of specific florae such as clostridium, bacteroides, thickenella, prevotella, Wehonor, streptococcus and klebsiella in an excrement sample; the limitation that traditional liver needle biopsy is invasive and imaging examination is insensitive to early-stage lesions is avoided.

The invention relates to a liver cirrhosis patient diet recommendation method, system and device based on machine learning, a medium and a computer program.The recommendation method comprises the steps that features are extracted through a graph convolutional network, a multi-dimensional patient feature map is constructed, and a multi-task deep reinforcement learning framework is established based on the feature map; the nutritional requirements of the patient are quantitatively analyzed, the complication risk is dynamically evaluated, and the diet preference mode is identified. Data distribution offset is monitored through an online incremental learning module, model parameters are updated through an adversarial domain adaptation algorithm, and dynamic feature drift compensation is achieved. And fusing the output information of the multi-task framework and the compensated data, generating a hierarchical diet decision tree, carrying out Monte Carlo tree search on a food material knowledge graph based on a patient state vector, and balancing nutrition and experience in combination with a reward mechanism to obtain a diet recommendation decision. Compared with the prior art, a personalized diet scheme can be provided for the patients with cirrhosis, and the treatment effect and the life quality are improved.

The invention belongs to the technical field of hepatic fibrosis detection, and discloses a positioning marking device for noninvasive hepatic fibrosis detection of patients with liver cirrhosis. The magnetic resonance monitoring mechanism is arranged at one end of the supporting seat; according to the technical scheme, the positioning plate, the driving gear and the scale plate are arranged, the driving motor set is driven, so that the output end of the driving motor set drives the movable bed to move towards the interior of the magnetic resonance monitoring mechanism to a proper position, and then the magnetic resonance monitoring mechanism can carry out positioning mark point recording on the detection position of a patient; then a power motor is started to drive a driving gear to rotate to drive a movable frame and a positioning plate to move, so that the positioning plate is attached to the movable bed, at the moment, recording can be carried out when the positioning plate moves to a certain position of a scale plate, and finally the half body shape distance of a patient entering the magnetic resonance monitoring mechanism is marked; therefore, the patient can be accurately positioned during subsequent reexamination, and the detection efficiency is greatly improved.

Methods for early detection of certain diseases, including eurodegenerative disease, chronic inflammation, Liver Cirrhosis and non-neoplastic dysregulation of cellular growth are provided. These methods utilize cell free DNA (cfDNA) fragmentomes as biomarkers that distinguish specific diseases.

The invention relates to the technical field of medicines, in particular to application of allogenic liver precursor cells in preparation of a medicine for treating liver cirrhosis, and the liver cirrhosis is decompensated liver cirrhosis. The allogenic liver precursor cells degrade extracellular matrix, fibroblast growth factor (FGF) and hepatocyte growth factor (HGF) through paracrine MMPs to promote hepatocyte regeneration and repair and the like, so that the liver cirrhosis is relieved and improved.

The application discloses an intestinal microbial marker combination for cirrhosis diagnosis and application thereof, which is composed of 8 specific intestinal bacterial species. The application accurately identifies the core combination from 181 differential characteristics by performing metagenomic sequencing on fecal samples of cirrhosis patients and healthy controls, and combining random forest, LASSO regression and recursive feature elimination algorithms. The random forest diagnosis model based on the 8 markers realizes an excellent performance of area under curve (AUC) 0.841, sensitivity 84.3% and specificity 83.7% on a completely independent test set, and the performance does not decrease compared with the full feature model in the case of reducing the number of characteristics by 86.9%. The marker combination provided by the application is highly simplified and has strong discrimination, and provides a clear and efficient microbiological basis and technical scheme for developing a cirrhosis non-invasive diagnosis kit, a gene chip and other products based on intestinal flora.

The invention relates to the technical field of medical information processing, in particular to a liver cirrhosis prognosis risk detection system. After the system detects the liver of the patient every time, the image cirrhosis risk can be quantified from the morphological change of the liver area by using the image data. And determining the disease progress index according to the difference between the actual detection data and the prediction data and the non-standardization degree of the prognosis response. And determining the drug adjustment degree by using the drug adjustment data so as to obtain the liver cirrhosis progression index. And quantizing the data hysteresis lag and liver cirrhosis progression index to jointly adjust the detection frequency of the system. The system can effectively respond to the illness state of a patient, and an effective early warning signal is generated when detection is needed to remind medical staff to conduct liver detection.

The invention discloses a non-invasive portal vein hemodynamic parameter measuring method and device and a medium, and relates to the technical field of medical detection equipment and biomedical signal processing.The method comprises the steps that abdominal epidermal potential distribution data is collected, a conductivity change area is recognized, and a portal vein trunk three-dimensional thermodynamic diagram is generated; peak coordinates of the portal vein trunk three-dimensional thermodynamic diagram are extracted, a portal vein trunk space positioning coordinate set is obtained, a graphene quantum tunneling sensor is driven to be attached to the abdominal skin surface of the patient based on the portal vein trunk space positioning coordinate set, and an attachment ready signal is output; based on the attachment ready signal, an original current data flow is collected, temperature drift correction is performed on the original current data flow, the original current data flow is converted into an instantaneous flow velocity, and a time-flow velocity sequence is generated. The microcosmic dynamic of early portal extravasated blood is captured, the pathological low-speed event which cannot be detected by the traditional technology is identified, and a non-invasive early warning index is provided for the liver cirrhosis progress risk.